Nucleon Nutrition Retatrutide 5 mg – Triple Receptor Agonis

Retatrutide is an advanced research peptide attracting exceptional interest in the field of metabolic and body-weight regulation studies. What makes Retatrutide unique is its triple agonist mechanism, targeting GLP-1, GIP, and glucagon receptors simultaneously — a direction currently considered one of the most advanced approaches in metabolic research.

Unlike compounds acting on a single pathway, Retatrutide allows researchers to explore the combined hormonal signaling involved in:

• appetite and satiety regulation,

• glucose metabolism and insulin response,

• energy expenditure and adipose tissue metabolism.

This triple-pathway interaction opens new perspectives for studying synergistic metabolic regulation, making Retatrutide one of the most innovative peptides available in the research chemical space today.

Important: This product is sold strictly as a Research Chemical.
Not for human or animal consumption.
Intended exclusively for laboratory and scientific research purposes.

Metafield: Composition

Form: Lyophilized powder (vial)
Active compound: Retatrutide

Metafield: Package / Serving

Package: 1 vial
Content: 5 mg per vial

Metafield: Active Ingredients

Active ingredients (per vial):

• Retatrutide – 5 mg

Metafield: Nutritional Value

Not applicable – this product is not a food or dietary supplement.

4 Key Research Advantages

• Triple receptor agonist profile (GLP-1 / GIP / glucagon) for advanced metabolic studies

• Supports research on appetite and satiety signaling pathways

• Suitable for investigations related to glucose regulation and insulin response

• Enables exploration of energy expenditure and fat metabolism mechanisms

Metafield: Intended Use

For research and laboratory use only.
Not intended for human or animal use.
Use exclusively by qualified professionals in accordance with laboratory protocols, safety standards, and applicable regulations.

1. New England Journal of Medicine – "Retatrutide, a Triple Hormone Receptor Agonist, for Obesity"
2. The Lancet – "Efficacy and safety of retatrutide in patients with type 2 diabetes"
3. Nature Metabolism – "Triple hormone receptor agonists: a new era in obesity treatment"